JP2007529484A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529484A5
JP2007529484A5 JP2007503401A JP2007503401A JP2007529484A5 JP 2007529484 A5 JP2007529484 A5 JP 2007529484A5 JP 2007503401 A JP2007503401 A JP 2007503401A JP 2007503401 A JP2007503401 A JP 2007503401A JP 2007529484 A5 JP2007529484 A5 JP 2007529484A5
Authority
JP
Japan
Prior art keywords
ethyl
alkyl
methyl
amino
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007503401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529484A (ja
Filing date
Publication date
Priority claimed from GBGB0405937.4A external-priority patent/GB0405937D0/en
Application filed filed Critical
Publication of JP2007529484A publication Critical patent/JP2007529484A/ja
Publication of JP2007529484A5 publication Critical patent/JP2007529484A5/ja
Pending legal-status Critical Current

Links

JP2007503401A 2004-03-16 2005-03-15 ピラゾロ[3,4−b]ピリジン化合物、およびPDE4阻害剤としてのその使用 Pending JP2007529484A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405937.4A GB0405937D0 (en) 2004-03-16 2004-03-16 Compounds
PCT/GB2005/000976 WO2005090353A1 (en) 2004-03-16 2005-03-15 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

Publications (2)

Publication Number Publication Date
JP2007529484A JP2007529484A (ja) 2007-10-25
JP2007529484A5 true JP2007529484A5 (cg-RX-API-DMAC7.html) 2008-05-01

Family

ID=32117821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503401A Pending JP2007529484A (ja) 2004-03-16 2005-03-15 ピラゾロ[3,4−b]ピリジン化合物、およびPDE4阻害剤としてのその使用

Country Status (5)

Country Link
US (1) US7465743B2 (cg-RX-API-DMAC7.html)
EP (1) EP1735315A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007529484A (cg-RX-API-DMAC7.html)
GB (1) GB0405937D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005090353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2005090354A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
CA2611376C (en) * 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Therapeutic agents
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) * 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
WO2009147476A1 (en) * 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Itk阻害剤として使用されるピリミジン誘導体
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 pi3k 억제제
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
WO2016123392A2 (en) * 2015-01-29 2016-08-04 Sanford-Burnham Medical Research Institute Pyrazolopyrimidines as inhibitors of glucocorticoid receptor translocation
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201813791D0 (en) * 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US4072681A (en) * 1977-03-02 1978-02-07 E. R. Squibb & Sons, Inc. 3,7-Dihydro- and 1,7-dihydro-4H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-4-ones
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体

Similar Documents

Publication Publication Date Title
JP2007529486A5 (cg-RX-API-DMAC7.html)
JP5552121B2 (ja) ロイコトリエン産生のインドリジン阻害剤
CN101263130A (zh) 2-苯胺-4-芳基取代的噻唑衍生物
JP2007529485A5 (cg-RX-API-DMAC7.html)
JP2009510043A5 (cg-RX-API-DMAC7.html)
US20130065895A1 (en) Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction
JP2012502067A5 (cg-RX-API-DMAC7.html)
JP2013519724A5 (cg-RX-API-DMAC7.html)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
KR20170094263A (ko) Nadph 옥시다제 억제제인 아미도 티아디아졸 유도체
JP2016512208A (ja) 炎症性障害の治療のための化合物及びその医薬組成物
JP2013520407A5 (cg-RX-API-DMAC7.html)
TW201333012A (zh) 咪唑并吡咯啶酮化合物
JP2004534826A5 (cg-RX-API-DMAC7.html)
RU2006131304A (ru) Производные имидазо[1,2-c]пиримидинилуксусной кислоты
JP2013515032A5 (cg-RX-API-DMAC7.html)
JP2018501315A5 (cg-RX-API-DMAC7.html)
JP2016503785A5 (cg-RX-API-DMAC7.html)
JP2012522748A5 (cg-RX-API-DMAC7.html)
US10160762B2 (en) 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
JP2018508553A5 (cg-RX-API-DMAC7.html)
KR20250081951A (ko) 금속 채널 활성화제를 포함하는 병용 요법
WO2018226771A1 (en) Pyrazolopyrimidine pde9 inhibitors
JP2018021042A (ja) アルファ7ニコチン性アセチルコリン受容体アゴニストの使用
JP2010500334A5 (cg-RX-API-DMAC7.html)